Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Collegium Pharmaceutical (Nasdaq: COLL) announced inducement equity grants made on June 1, 2026 under its 2026 Inducement Plan.

Rhea-AI Summary

Collegium Pharmaceutical (Nasdaq: COLL) announced inducement equity grants made on June 1, 2026 under its 2026 Inducement Plan. The company granted 50,305 restricted stock units (RSUs) to 34 newly hired non-executive employees, with three-year, service-based vesting, under Nasdaq Listing Rule 5635(c)(4).

Positive

• 50,305 RSUs granted to 34 new non-executive hires
• Three-year vesting schedule encourages employee retention and alignment
• 2026 Inducement Plan adopted May 11, 2026 to support hiring

Negative

• Future issuance of up to 50,305 shares may increase share count
• Equity awards granted outside stockholder-approved equity incentive plan

Argus Jun 5 session

+2.11% close to close Open Argus

Details

News Market Reaction – COLL

In the Jun 5 session, COLL gained 2.11%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details inducement equity awards totaling 50,305 RSUs to 34 newly hired non-execut...

Analysis

This announcement details inducement equity awards totaling 50,305 RSUs to 34 newly hired non-executive employees under a 2026 Inducement Plan, vesting over roughly three years starting June 10, 2027. Such grants modestly increase share-based compensation but are common for talent recruitment. In context of recent strong Q1 2026 results and the AZSTARYS acquisition, investors may watch overall dilution trends, insider activity, and future earnings updates for a fuller picture.

Key Figures

Inducement RSUs granted: 50,305 RSUs New hires granted: 34 individuals Initial vesting date: June 10, 2027 +2 more

Inducement RSUs granted

50,305 RSUs

Aggregate grants under 2026 Inducement Plan on June 1, 2026

New hires granted

34 individuals

Non-executive newly hired employees receiving inducement RSUs

Initial vesting date

June 10, 2027

One-third of RSUs scheduled to vest

Remaining vesting period

2 years

Balance vests in equal annual installments after initial vesting

Grant date

June 1, 2026

Date inducement RSUs were awarded

Historical Context

5 past events · Latest: May 27

5 events

1. May 27

   Conference participation

   24h Move

   -0.3%

   Announcement of Jefferies Global Healthcare Conference fireside chat and webcast.

2. May 12

   Product acquisition

   24h Move

   -0.3%

   Completion of AZSTARYS acquisition with raised 2026 revenue and EBITDA guidance.

3. May 07

   Quarterly earnings

   24h Move

   +7.7%

   Q1 2026 revenue growth, solid EBITDA, cash balance, and AZSTARYS closing outlook.

4. Apr 23

   Earnings date set

   24h Move

   -2.4%

   Scheduling of Q1 2026 earnings release and accompanying conference call.

5. Apr 08

   Investor conferences

   24h Move

   +2.0%

   Participation in Needham virtual healthcare conference and Piper Sandler symposium.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, rsus, nasdaq listing rule 5635(c)(4), equity incentive plan

4 terms

restricted stock units financial

"The Company granted 50,305 restricted stock units (RSUs), in aggregate..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"Each RSU represents a contingent right to receive one share..."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

equity incentive plan financial

"outside of the Company's stockholder-approved equity incentive plan..."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOUGHTON, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it awarded inducement grants on June 1, 2026 under the Company's 2026 Inducement Plan (the 2026 Inducement Plan).

The Company granted 50,305 restricted stock units (RSUs), in aggregate, as a material inducement to the employment of 34 non-executive individuals newly hired by the Company. Each RSU represents a contingent right to receive one share of the Company’s common stock. One-third of the RSUs shall vest on June 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the employee’s continued service with the Company through each applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company’s common stock.

The above-described RSUs were granted outside of the Company's stockholder-approved equity incentive plan pursuant to the 2026 Inducement Plan, which was adopted by the Company's board of directors (the Board) on May 11, 2026 as a material inducement to the individuals entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions.

With a portfolio of differentiated ADHD medications, anchored by JORNAY PM® (methylphenidate HCl) and AZSTARYS® (serdexmethylphenidate and dexmethylphenidate), and an established leadership position in responsible pain management, Collegium leads with the scientific rigor and commercial expertise to deliver treatment options around how people live their lives. For more information, please visit collegiumpharma.com or find us on LinkedIn.

Investor Contact:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com

Media Contact:
Jessica Cotrone
Senior Vice President, Corporate Communications & Corporate Affairs
communications@collegiumpharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement grants did Collegium Pharmaceutical (NASDAQ: COLL) announce on June 5, 2026?

Collegium Pharmaceutical announced it granted 50,305 restricted stock units to 34 newly hired non-executive employees. According to Collegium, these awards were made under the 2026 Inducement Plan as a material inducement to employment, consistent with Nasdaq Listing Rule 5635(c)(4).

How many RSUs did Collegium Pharmaceutical (COLL) grant under the 2026 Inducement Plan?

Collegium granted an aggregate of 50,305 restricted stock units under its 2026 Inducement Plan. According to Collegium, these RSUs were awarded to 34 newly hired non-executive employees as a material inducement for joining the company, outside the stockholder-approved equity incentive plan.

What is the vesting schedule for Collegium Pharmaceutical’s June 1, 2026 RSU grants?

The RSUs vest over three years, starting June 10, 2027. According to Collegium, one-third vests on June 10, 2027, with the remaining RSUs vesting in equal annual installments over the following two years, subject to continued service on each vesting date.

Are Collegium Pharmaceutical’s June 2026 inducement RSUs part of its stockholder-approved equity plan?

The June 2026 inducement RSUs were granted outside Collegium’s stockholder-approved equity incentive plan. According to Collegium, they were issued under the separate 2026 Inducement Plan, adopted by the board on May 11, 2026, in line with Nasdaq Listing Rule 5635(c)(4).

Why did Collegium Pharmaceutical (COLL) adopt the 2026 Inducement Plan?

Collegium adopted the 2026 Inducement Plan as a material inducement for new employees to join the company. According to Collegium, the plan, approved by the board on May 11, 2026, supports inducement grants permitted under Nasdaq Listing Rule 5635(c)(4).